 BOSTON, Feb. 03, 2021 GLOBE NEWSWIRE -- Rhythm Pharmaceuticals, Inc. Nasdaq: RYTM, a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced a proposed public offering of 150 million of shares of its common stock. All shares in the offering will be offered by Rhythm. In addition, Rhythm intends to grant the underwriters a 30-day option to purchase up to an additional 22.5 million of shares of common stock at the public offering price, less the underwriting discount and commission. 